USPTO serial 79390167
MEGALLOLINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 14, 2025
- Examiner
- SANTOMARTINO, MARTHA L
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEGALLOLINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebeccah Gan
Rebeccah Gan Muncy, Geissler, Olds & Lowe, P.C.125 S. Royal St.Alexandria, VA 22314United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for research; stem cells for scientific purposes; nutrition agents, namely, cell culture reagents for scientific and research use for processing living cells other than for medical purposes; cell culture media other than for medical and veterinary purposes | ACTIVE | — |
| 005 | Pharmaceutical products for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; pharmaceutical preparations for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; stem cells for medical or veterinary use; pluripotent stem cells for medical use intended for cell and gene therapies; cultures of cell media for medical and veterinary use; surgical implants comprised of living tissues obtained from stem cells | ACTIVE | — |
| 042 | Laboratory research in the field of biotechnology; scientific research on stem cells; scientific research on the production of pluripotent stem cells by encapsulation; research and development in the field of stem cells, cell and gene therapy and biotechnology; pharmaceutical research and development; scientific laboratory services; providing information with respect to scientific research in the field of stem cells, cell and gene therapy and biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TREEFROG THERAPEUTICS
- Other trademarks owned by TREEFROG THERAPEUTICS
- Other trademarks owned by TREEFROG THERAPEUTICS
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named MEGALLOLINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 14, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 14, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 26, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 26, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 20, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 30, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 28, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 28, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 28, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 28, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 16, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 15, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 23, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 22, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |